Precision Medicine in Thoracic Oncology (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 26
Special Issue Editor
Interests: non-small cancer cells; lung cancer; medical oncology; thoracic tumours; early phase clinical trials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of a previous Special Issue on “Precision Medicine in Thoracic Oncology”(https://www.mdpi.com/journal/cancers/special_issues/Precision_Medicine_Thoracic_Oncology).
The past twenty years have witnessed an unprecedented development in technologies, which allow for a more precise definition of the genetic make-up of solid and hematological cancers, promoting the identification of molecular alterations consistently expressed in some kinds of tumors quite often characterized by a peculiar clinical behavior and response to target treatments. Among the tumors for which an extensive evaluation of genetic alterations has been rewarding are lung cancers, especially adenocarcinomas, now subclassified according to the expression of specific markers, which drive a personalized attempt to cure them. In this Special Issue of Cancers, we aim to collect contributions not only on the broader topic of lung cancer, but also regarding much less common thoracic neoplasms such as thymoma, mesothelioma, and neuroendocrine tumors. Contributions can be in the form of original articles, reviews, or commentaries aimed at providing a comprehensive update on ideas, discoveries, technologies, and approaches that are bringing precision oncology to the bedside of patients diagnosed with thoracic cancers.
Dr. Jessica Menis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- precision medicine
- thoracic oncology
- lung cancer
- thymoma
- mesothelioma
- thoracic NETs molecularly targeted therapy
- immunotherapy
- biomarkers
Related Special Issue
- Precision Medicine in Thoracic Oncology in Cancers (5 articles)
